<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00846846</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.0, 29 October 2008</org_study_id>
    <nct_id>NCT00846846</nct_id>
  </id_info>
  <brief_title>PROTECT Continued Access Post Marketing Surveillance Trial</brief_title>
  <acronym>PROTECT-CA</acronym>
  <official_title>Patient Related OuTcomes With Endeavor Versus Cypher Stenting Trial: PROTECT Continued Access Post Marketing Surveillance Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to expand safety information in patients treated with the Endeavor Drug Eluting&#xD;
      Stent System, or next generation model, a Continued Access (CA) study is added to the PROTECT&#xD;
      Trial. The amended study is &quot;PROTECT CONTINUED ACCESS&quot; (&quot;PROTECT CA&quot;).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a prospective, multicenter, non-randomized, single-arm, open-label post market&#xD;
      surveillance study designed to expand safety information in patients treated with the&#xD;
      Endeavor® Zotarolimus Eluting Coronary Stent System.&#xD;
&#xD;
      Since their introduction, Drug Eluting Stents (DES) have markedly decreased stent restenosis&#xD;
      and the clinical need for repeat revascularization frequently observed with bare metal stents&#xD;
      (BMS)1-10. However, the widespread use of DES has raised concerns regarding the occurrence of&#xD;
      late stent thrombosis (&gt; 30 days after stent implantation)12-14. Although the incidence might&#xD;
      seem low (0.2-0.7%)13,15-18 the high mortality and morbidity associated with stent&#xD;
      thrombosis, and the soaring number of stents implanted annually, make it a significant&#xD;
      medical problem.&#xD;
&#xD;
      The purpose of this trial was to investigate the long-term clinical safety and efficacy of&#xD;
      the Endeavor drug eluting stent in a large and higher risk patient population, which more&#xD;
      closely reflects clinical practice today. Both unstable and stable patients with single or&#xD;
      multivessel disease and complex lesions were eligible for enrollment.&#xD;
&#xD;
      The selected primary endpoint was stent thrombosis, defined as definite and probable stent&#xD;
      thrombosis according to the ARC definition, at 3 years. The main secondary endpoints were the&#xD;
      composite of death or cardiac death combined with large or all non-fatal myocardial&#xD;
      infarction, which are the typical clinical manifestations of stent thrombosis. These events&#xD;
      are adjudicated by a clinical events committee.&#xD;
&#xD;
      1.2 Study Endpoints 1.2.1 Primary Endpoint: The overall stent thrombosis rate defined as&#xD;
      definite and probable stent thrombosis according to the ARC definition at 3 years 1.2.2&#xD;
      Secondary Endpoints:&#xD;
&#xD;
      Main Secondary Endpoints include:&#xD;
&#xD;
        -  Composite endpoint of total death and number of patients with all non-fatal myocardial&#xD;
           infarction at 3 years&#xD;
&#xD;
        -  Composite endpoint of cardiac death and number of patients with all non-fatal myocardial&#xD;
           infarction at 3 years&#xD;
&#xD;
        -  Composite endpoint of total death and number of patients with large non-fatal myocardial&#xD;
           infarction at 3 years&#xD;
&#xD;
        -  Composite endpoint of cardiac death and number of patients with large non-fatal&#xD;
           myocardial infarction at 3 years&#xD;
&#xD;
      Additional secondary endpoints include:&#xD;
&#xD;
        -  Total Death and subcategories of Death&#xD;
&#xD;
        -  Large and all Myocardial Infarction (MI)&#xD;
&#xD;
        -  Stent thrombosis defined as definite, probable and possible&#xD;
&#xD;
        -  Composite score of clinical outcomes (death, myocardial infarction, stroke and&#xD;
           revascularization) *&#xD;
&#xD;
        -  Major Adverse Cardiac and Cerebral Events (MACCE)&#xD;
&#xD;
        -  Stroke (hemorrhagic in nature while on clopidogrel)&#xD;
&#xD;
        -  Bleeding complications in general&#xD;
&#xD;
        -  Target lesion revascularization (TLR)&#xD;
&#xD;
        -  Target vessel revascularization (TVR)&#xD;
&#xD;
        -  Non target vessel revascularization (non TVR)&#xD;
&#xD;
        -  Procedural success&#xD;
&#xD;
        -  Device success&#xD;
&#xD;
        -  Lesion success&#xD;
&#xD;
        -  Endpoints will be calculated at the follow-up time points and for the mean follow-up&#xD;
           period.&#xD;
&#xD;
             -  The composite score of clinical outcomes (death, myocardial infarction, stroke and&#xD;
                revascularization) constructed from a patient population according to the Delphi&#xD;
                method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Evaluate Overall Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System in a Patient Population Requiring Stent Implantation</measure>
    <time_frame>3 years</time_frame>
    <description>The primary endpoint rate of ARC-defined definite or probable stent thrombosis at 3 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions.</measure>
    <time_frame>3 years</time_frame>
    <description>Total death and and number of patients with all non-fatal myocardial infarction. Cardiac death and number of patients with all non-fatal myocardial infarction. Total death and number of patients with large non-fatal myocardial infarction. Cardiac death and number of patients with large non-fatal myocardial infarction.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1018</enrollment>
  <condition>Coronary Artery Disease, Autosomal Dominant, 1</condition>
  <arm_group>
    <arm_group_label>Endeavor® Zotarolimus Eluting Coronary Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endeavor® Zotarolimus Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endeavor® Zotarolimus Eluting Coronary Stent System</intervention_name>
    <description>Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation</description>
    <arm_group_label>Endeavor® Zotarolimus Eluting Coronary Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is &gt; 18 years of age (or minimum age as required by local regulations).&#xD;
&#xD;
          2. The patient or patient's legal representative has consented to participate and has&#xD;
             authorized the collection and release of his medical information by signing the&#xD;
             &quot;Patient Informed Consent Form&quot;.&#xD;
&#xD;
          3. All lesions requiring interventions (target lesions - one to a maximum of four) in one&#xD;
             or more native coronary arteries are amendable for implantation of one or more&#xD;
             Endeavor® Zotarolimus Eluting Coronary Stent System.&#xD;
&#xD;
          4. Patient indication, lesion length and vessel diameter of the target lesion(s) are&#xD;
             according to the 'Indications for Use' as mentioned in the 'Instructions for Use' that&#xD;
             comes with every Endeavor® Zotarolimus Eluting Coronary Stent System. Please check the&#xD;
             'Instructions for Use' that comes with the product. Please be aware that the&#xD;
             'Instructions for Use' may be subject to change during the course of the study.&#xD;
&#xD;
        5 The patient is willing and able to cooperate with study procedures and required follow up&#xD;
        visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women with known pregnancy or who are lactating.&#xD;
&#xD;
          2. Planned elective surgery necessitating discontinuation of clopidogrel within the&#xD;
             regular planned period of clopidogrel administration.&#xD;
&#xD;
          3. Patients expected not to be compliant with the anti-platelet and/or anticoagulation&#xD;
             therapy regimen.&#xD;
&#xD;
          4. Previous brachytherapy.&#xD;
&#xD;
          5. Previous implantation of a drug eluting stent.&#xD;
&#xD;
          6. Previous implantation of a bare metal stent in the preceding year.&#xD;
&#xD;
          7. Simultaneous or planned intervention other non cardiac vessels including but not&#xD;
             limited to renal artery or carotid artery.&#xD;
&#xD;
          8. Current medical condition with a life expectancy of less than 3 years.&#xD;
&#xD;
          9. Manifest acute severe heart failure (Killip class III-IV).&#xD;
&#xD;
         10. The patient is currently, and during the first 3 years of the PROTECT trial,&#xD;
             participating in another investigational device or drug study that clinically&#xD;
             interferes with the PROTECT-study endpoints; or requires coronary angiography or other&#xD;
             coronary artery imaging procedures. The patient may only be enrolled in the&#xD;
             PROTECT-study once.&#xD;
&#xD;
         11. Patients with medical conditions that preclude the follow-up as defined in the&#xD;
             protocol or that otherwise limits participation in this study.&#xD;
&#xD;
         12. Patients on warfarin or similar anti-coagulant therapy.&#xD;
&#xD;
         13. Patients with hypersensitivity or allergies to one of the drugs or components&#xD;
             indicated in the Instructions for Use.&#xD;
&#xD;
         14. Patients who are judged to have a lesion that prevents complete inflation of an&#xD;
             angioplasty balloon.&#xD;
&#xD;
         15. Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated.&#xD;
&#xD;
        16 Transplant patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Bousquette</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic Cardiovascular</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <results_first_submitted>May 30, 2014</results_first_submitted>
  <results_first_submitted_qc>May 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 2, 2014</results_first_posted>
  <last_update_submitted>April 13, 2015</last_update_submitted>
  <last_update_submitted_qc>April 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1018 patients were enrolled from February 2009 until November 2009 in 48 participating hospitals in USA.</recruitment_details>
      <pre_assignment_details>Subjects were excluded from participation if they did not meet inclusion/exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Endeavor® Zotarolimus Eluting Coronary Stent System</title>
          <description>Endeavor® Zotarolimus Eluting Coronary Stent System&gt;&#xD;
&gt; Endeavor® Zotarolimus Eluting Coronary Stent System: Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1018"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="943">Study ongoing but not recruiting participants.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Endeavor® Zotarolimus Eluting Coronary Stent System</title>
          <description>Endeavor® Zotarolimus Eluting Coronary Stent Implantation in a patient population requiring stent implantation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1018"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.16" lower_limit="31" upper_limit="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="744"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Evaluate Overall Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System in a Patient Population Requiring Stent Implantation</title>
        <description>The primary endpoint rate of ARC-defined definite or probable stent thrombosis at 3 years.</description>
        <time_frame>3 years</time_frame>
        <population>Of the one thousand and eighteen (1018) ITT patients, a total of nine hundred and forty seven (947) patients were included in the primary endpoint analysis. These patients had at least 1050 days of follow-up or had experienced stent thrombosis prior to 1080 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Endeavor® Zotarolimus Eluting Coronary Stent System</title>
            <description>Intention to treat analyis has been used.</description>
          </group>
        </group_list>
        <measure>
          <title>To Evaluate Overall Stent Thrombosis Rate of the Endeavor® Zotarolimus Eluting Coronary Stent System in a Patient Population Requiring Stent Implantation</title>
          <description>The primary endpoint rate of ARC-defined definite or probable stent thrombosis at 3 years.</description>
          <population>Of the one thousand and eighteen (1018) ITT patients, a total of nine hundred and forty seven (947) patients were included in the primary endpoint analysis. These patients had at least 1050 days of follow-up or had experienced stent thrombosis prior to 1080 days.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="947"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" lower_limit="0.6" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions.</title>
        <description>Total death and and number of patients with all non-fatal myocardial infarction. Cardiac death and number of patients with all non-fatal myocardial infarction. Total death and number of patients with large non-fatal myocardial infarction. Cardiac death and number of patients with large non-fatal myocardial infarction.</description>
        <time_frame>3 years</time_frame>
        <population>Main secondary endpoint results for the ITT population are similar to the primary endpoint analysis, a total of nine hundred and forty seven (947) ITT patients had sufficient follow-up or an event to be included in the main secondary endpoint analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Endeavor® Zotarolimus Eluting Coronary Stent System</title>
            <description>Intention to treat analyis has been used.</description>
          </group>
        </group_list>
        <measure>
          <title>Composites of (Cardiac) Death and (Large) Non-fatal Myocardial Infarctions.</title>
          <description>Total death and and number of patients with all non-fatal myocardial infarction. Cardiac death and number of patients with all non-fatal myocardial infarction. Total death and number of patients with large non-fatal myocardial infarction. Cardiac death and number of patients with large non-fatal myocardial infarction.</description>
          <population>Main secondary endpoint results for the ITT population are similar to the primary endpoint analysis, a total of nine hundred and forty seven (947) ITT patients had sufficient follow-up or an event to be included in the main secondary endpoint analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="947"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>the composite rate of death and/or MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="9.7" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>the composite rate of cardiac death and/or MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="6.6" upper_limit="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>composite rate of death and/or large MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8" lower_limit="6.2" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>composite rate of cardiac death and/or large MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.0" upper_limit="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Endeavor</title>
          <description>Medtronic Endeavor</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="415" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="36" subjects_affected="30" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="55" subjects_affected="49" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="31" subjects_affected="26" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" events="25" subjects_affected="12" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Cardiac Tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Coronary Artery Dissection</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>In-Stent Coronary Artery Restenosis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" events="28" subjects_affected="24" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="93" subjects_affected="69" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Unevaluable Event</sub_title>
                <counts group_id="E1" events="237" subjects_affected="151" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Vessel Puncture Site Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Stent Occlusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Thrombosis In Device</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac Enzymes Increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Electrocardiogram ST Segment Elevation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Arteriovenous Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="1018"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unevaluable Event</sub_title>
                <counts group_id="E1" events="190" subjects_affected="134" subjects_at_risk="1018"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For any publication or presentation of the Protected Materials or any portion thereof, a maunscript of the paper, abstract or any materials will be provided by Consultant to Sponsor for its approval at least sixty (60days) for manuscripts and thirty (30) days for presentations prior to outside submission. Medtronic shall have the right to request reasonable modifications of any manuscript or other materials to be published or presented.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Lisa Bousquette, Director Clinical Research Coronary and Renal Denervation</name_or_title>
      <organization>Medtronic Cardiovascular</organization>
      <email>lisa.r.bousquette@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

